Transcatheter Arterial Chemo Infusion/TACI for Breast Cancer Treatment: A Case Series

Bagaswoto Poedjomartono, Alan Anderson Bangun, Rifki Bachtiar

Abstract


Introduction:  Locally advanced breast cancer (LABC) is a large breast tumor with infiltration to surrounding muscle, skin, and lymph nodes, and sometimes followed by inflammatory breast cancer, a rapidly growing cancer that shows a swollen red lump on the skin. Transcatheter intraarterial chemo infusion (TACI) is considered a palliative therapy for inoperable cancer. This case report shows the qualitative results of TACI on LABC in three patients.

 

Case Presentation: Three female patients with LABC were diagnosed and treated at Dr. Sardjito General Hospital Yogyakarta over three years (2014–2016). The age ranged from 48 to 62 years, with a mean age of 56 years. Clinical features include lumps in breasts, soft tissue swelling, ulcers, dimpling of breast skin, nipple discharge, and pain sensation in the breast area. The three patients underwent the TACI procedure. Therapeutic response was evaluated by observing the clinical morphology of the lesions.

 

Conclusions: TACI showed potency as an efficient and effective alternative palliative therapy in the three LABC cases presented. However, further study is needed to inspect TACI’s efficacy and adverse effects in breast cancer cases to be used as evidence-based medicine.


Keywords


cancer, chemotherapy, interventional radiology, TACI, therapy

References


The Global Cancer Observatory. Cancer Incident in Indonesia. Int Agency Res Cancer. 2020;858:1–2.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.

Tryfonidis K, Senkus E, Cardoso MJ, Cardoso F. Management of locally advanced breast cancer-perspectives and future directions. Nat Rev Clin Oncol. 2015;12(3):147– 62.

Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol. 1954;30(5):969-977.

Lewandowski RJ, Geschwind JF, Liapi E, Salem R. Transcatheter intraarterial therapies: rationale and overview. Radiology. 2011;259(3):641-657.

Poedjomartono B, Pramiadi. The role of transcatheter arterial chemoinfusion (TACI) in unresectable adenocarcinoma colorectal: a case report. J Thee Med Sci Berk Ilmu Kedokt. 2019;51(03):270–81.

Nagahama K, Kawano D, Oyama N, Takemoto A, Kumano T, Kawakami J. Self-Assembling Polymer Micelle/Clay Nanodisk/Doxorubicin Hybrid Injectable Gels for Safe and Efficient Focal Treatment of Cancer. Biomacromolecules. 2015 Mar 9;16(3):880–9.

Smith L, Watson MB, O'Kane SL, Drew PJ, Lind MJ, Cawkwell L. The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays. Mol Cancer Ther. 2006 Aug;5(8):2115-20.

Wang X, Gan C, Li H, Wei Y, Zhu D, Yang G, et al. Main complications and results of treatment with intra-arterial infusion chemotherapy through the subclavian and thoracic arteries for locally advanced breast cancer. Mol Clin Oncol. 2013;1(4):745–8.

Collins, JM. Pharmacologic rationale for regional drug delivery. J Clin Oncol. 1984 May; 2(5):498-504.

Ellis JA, Banu M, Hossain SS, et al. Reassessing the Role of Intra-Arterial Drug Delivery for Glioblastoma Multiforme Treatment. J Drug Deliv.2015;2015:405735.

Okusaka T, Kasugai H, Shioyama Y, Tanaka K, Kudo M, Saisho H, et al. Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: A randomized phase III trial. J Hepatol. 2009;51(6):1030–6.

Aksoy S, Akce B, Kilickesmez O, Gursu RU, Cakir MS, Nazli MA, et al. Transcatheter Arterial Embolization for Controlling Severe Bleeding From Recurrent Locally- Advanced Breast Cancer. J Breast Health. 2016;12(3):137–40.

Ensminger WD. Intrahepatic arterial infusion of chemotherapy: Pharmacologic principles. Semin Oncol. 2002;29(2):119–25.

Koh J, Kim MJ. Introduction of a new staging system of breast cancer for radiologists: An emphasis on the prognostic stage. Korean J Radiol. 2019;20(1):69–82.

Loibl S, O’Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018 Apr 1;19(4):497–509.


Full Text: PDF

DOI: 10.33371/ijoc.v16i2.874

Article Metrics

Abstract view : 82 times
PDF - 36 times

Refbacks

  • There are currently no refbacks.


Copyright (c) 2022 Indonesian Journal of Cancer

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.